Evidence map›Paper›PMID 32483828›Full record

ArticleNeuropathology : official journal of the Japanese Society of Neuropathology2020

The autophagic marker p62 highlights Alzheimer type II astrocytes in metabolic/hepatic encephalopathy.

Ellen Gelpi, Jasmin Rahimi, Sigrid Klotz, Susanne Schmid, Gerda Ricken, Sara Forcen-Vega, Herbert Budka, Gabor G Kovacs

Open access · hybridAbstract read
In one paragraph

Article in Neuropathology : official journal of the Japanese Society of Neuropathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Oedematic-atrophic astrocytes in hepatic encephalopathy.Acta neuropathologica communications · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Hepatic encephalopathy.Nature reviews. Disease primers · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Ellen GelpiDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0003-2948-4187
Jasmin RahimiDepartment of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Danube Hospital, Vienna, Austria.
Sigrid KlotzDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
Susanne SchmidDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
Gerda RickenDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
Sara Forcen-VegaNeurology Department, Germans Trias i Pujol Hospital, Autonomous University of Barcelona, Barcelona, Spain.
Herbert BudkaDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
Gabor G KovacsDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
Medical University of Vienna · ATConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESKarl Landsteiner Society · ATUniversitat Autònoma de Barcelona · ESUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic/hepatic encephalopathy is neuropathologically characterized by the presence of Alzheimer type II astrocytes (AA II) with large and clear nuclear morphology. To date, there is no good immunohistochemical marker to better identify these cells. Here, we assessed cases of hepatic encephalopathy of different etiologies by immunohistochemistry using an anti-p62 antibody. We observed peripheral or diffuse nuclear staining of variable intensity in AA II in all cases but not in normal controls or reactive astrocytes. We conclude that p62 is a useful immunohistochemical marker for the identification of AA II and may be helpful for the neuropathological diagnosis of metabolic/hepatic encephalopathy in difficult or equivocal cases.

Indexed as

AdolescentAgedAntibodies, MonoclonalAstrocytesAutophagyBiomarkersChild, PreschoolFemaleHepatic EncephalopathyHumansInfantMaleMiddle AgedRNA-Binding ProteinsAntibodies, MonoclonalBiomarkersP62 protein, humanRNA-Binding ProteinsAlzheimer type II astrocytesastrogliopathyhepatic encephalopathymetabolic encephalopathyp62

Identifiers

PMID32483828
PMCPMC7496304
OpenAlexW3028971414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.